| Previous close | 6.50 |
| Open | 6.50 |
| Bid | 1.65 |
| Ask | 3.70 |
| Strike | 52.50 |
| Expiry date | 2024-12-20 |
| Day's range | 6.50 - 6.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
PR NewswireInsmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has called all $225 million aggregate principal amount of its outstanding 1.75% Convertible Senior Notes Due 2025 (the "Notes") (CUSIP No. 457669AA7) for redemption on August 9, 2024 (the "Redemption Date"). Insmed is redeeming the Notes as permitted under Section 11.03 of the indenture governing the Notes (the "Indenture")
- PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 15 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
- PR Newswire
Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Monday, June 10, 2024, at 10:00 a.m. ET.
